Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $44,540.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 8,500 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00. Following the transaction, the chief executive officer directly owned 3,620,995 shares of the company’s stock, valued at $18,974,013.80. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Trading Down 6.2%

Shares of SOPH opened at $4.88 on Friday. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The firm’s 50-day moving average is $4.98 and its two-hundred day moving average is $4.89. SOPHiA GENETICS SA has a twelve month low of $2.59 and a twelve month high of $5.70. The firm has a market capitalization of $334.23 million, a P/E ratio of -9.38 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds have recently made changes to their positions in SOPH. Savvy Advisors Inc. purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $48,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. Finally, Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.